Colorectal Cancer

Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Nivolumab with ipilimumab elicited improvements to progression-free survival in patients with microsatellite instability–high colorectal cancer.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.